100 haemodialysis and 50 peritoneal dialysis patients in its chronic dialysis programme at any one time, with concomitant pressure to transplant patients and free dialysis space. A strategy has been adopted to offer RRT to the healthiest and the young. As in other centres in SA, prospective patients are presented at weekly multidisciplinary assessment meetings to decide whether they are suitable for renal replacement. 6 Criteria, including fitness to undergo renal transplantation, age, co-morbidity, social circumstances and psychological state, are strictly applied. Patients aged >60 years are refused RRT and there is preferential allocation to patients without accompanying chronic co-morbidity. Determining the most ethical allocation requires considerations of justice and equity. Moosa and Kidd draw attention to the dangers and injustice inherent in such a rationing of this scarce resource.
Before deciding to commence HIV-positive-to-positive transplantation at GSH, HIV-infected patients with ESRF were believed to be poor transplant candidates and were not accepted for RRT. Moreover, until 2004, HIV-infected patients were deemed unsuitable for renal transplantation owing to the lack of an ART programme, and the dangers of using immunosuppressive antirejection drugs in the absence of HAART. This concern has abated as good outcomes have been confirmed after transplantation in HIVinfected patients receiving HAART. 7, 8 
Solid organ transplantation in HIVinfected patients
Studies from the USA have shown that there is no difference in patient outcome, graft survival and opportunistic infection rates in HIV-infected patients undergoing transplant, compared with HIV-seronegative patients. [9] [10] [11] Many immunosuppressive drugs controlling rejection in transplant patients retard HIV replication; 12, 13 mycophenolate mofetil acts synergistically with some nucleoside analogues, and sirolimus down-regulates the CCR5 co-receptor on CD4+ T-cells, which plays a vital role in entry of HIV into the cell. 14, 15 More rapid immune reconstitution has also been reported in HIVpositive patients treated with cyclosporine (as anti-rejection therapy) and HAART versus HAART alone. 16 With expanding access to HAART, practice in South Africa now permits allocation of RRT to HIV-infected patients. However, the increasing numbers of patients, the insufficiency of available dialysis slots and the lack of HIV-negative organ donors, severely limits the 
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ability to offer RRT (even to HIV-negative patients). 6 We therefore concluded that transplanting a kidney from an HIV-infected donor (that would otherwise have been discarded) into an HIV-positive recipient represented a viable option, given the potentially large pool of HIV-infected donors (10 -20% HIV seroprevalence in potential donors referred to Transplant Co-ordinators in Cape Town and Johannesburg).
However, there are several theoretical concerns to this approach. Firstly, there is the risk that the donor kidney will act as a 'Trojan horse' , super-infecting the recipient with a recombinant form of virus or with virus of a different clade. 17, 18 However, as HAART is equally effective in suppressing all clades of HIV, replication of superinfecting HIV should rapidly be suppressed, particularly as it is our practice that the recipient is prescribed a protease inhibitor-based regimen following transplantation. There is a further theoretical risk that the donor will transmit drug-resistant virus. 19 Although this risk is very small at this stage of the HIV epidemic in SA, we accept that resistance rates will inevitably increase over time, as more patients commence HAART and fail first-and second-line therapy. Future strategies to suppress potentially resistant virus would include the use of donor virus genotyping to inform appropriate ART prescribing. The donor kidney may also act as a 'Trojan horse' for other infectious diseases such as tuberculosis, cytomegalovirus, etc. To obviate this, we measure the urine protein-creatinine ratio and perform a baseline renal biopsy to detect donor renal disease before implantation.
In 2010 we reported our experience with the first 4 kidney transplants from HIV-positive donors to HIV-positive recipients. 20 Since then, 10 more HIV-positive to HIV-positive renal transplants have been performed (at GSH and the UCT Private Hospital). In all patients, surgery was uncomplicated. Following transplantation, ART was recommenced on day 1 or day 2 and all patients received antithymocyte globulin or thymoglobulin induction therapy and an antirejection regimen consisting of mycophenolate mofetil, tacrolimus and prednisone. All patients are currently 1 -4 years post-transplant and have undetectable viral loads (<50 copies/ml).
In conclusion, we have shown that transplanting HIV-infected patients with ESRF with kidneys from HIV-positive donors represents a significant advance, benefiting patients with ESRF due to HIVAN, within our resource-constrained context.
